In a 2-year follow up of patients with and without diabetes, the Resolute DES showed "consistently low event rates out to two years for both groups, despite the higher-risk nature of the diabetes patient population," according to a press release.
Rates of target lesion failure were 7.1% for patients without diabetes and 9.6% for patients with diabetes in a study pooling clinical trial results from 878 "standard risk" diabetes patients and 1,903 patients without diabetes.
Medtronic in February won FDA clearance for its Resolute Integrity DES to treat diabetic patients with coronary artery disease, which make up about ⅓ of the CAD population.
"They tend to have smaller and often tortuous arteries, longer lesions, diffuse disease and a higher rate of treatment failures including relatively high rates of repeat procedures and stent thrombosis," Medtronic told MassDevice at the time. "As a result, many of these patients have undergone open heart surgery."
MDT shares were down about 0.5% to $36.89 as of about 2:30 p.m. today.
Tengion struggles, but may find refuge in Medtronic
Regenerative technology company Tengion (NSDQ:TNGN)
is running low on cash reserves and is on the edge of Nasdaq delisting, but a partnership with med-tech titan Medtronic (NYSE:MDT), a participant in past funding rounds, could help the company bolster its coffers.
Uroplasty soars on 40% boost in Q4 sales
Minneapolis-based incontinence devices maker Uroplasty (NSDQ:UPI) posted a 39.4% increase in sales and cut losses in half during the 3 months ended March 31. The company beat analysts’ expectations by 4¢, posting losses of $573,000, or 3 cents per share.
Full year 2012 sales grew 49.1% to $20.6 million, and losses shrank 8.6% to $4.3 million.
UPI shares spiked 19.3% to $3.99 around 2:15 p.m. today.
NeuroMetrix targets investors
Waltham, Mass.-based NeuroMetrix (NSDQ:NURO) hired IRG LLC to act as its investor relations agency, leading to speculation that the company may be on the auction block. The company said it would "implement a campaign targeting portfolio managers, analysts, and the retail community with the goal of increasing investor awareness of NeuroMetrix and its role in the fast-growing diabetes sector."
Allscripts shareholders launch proxy war
One of Allscripts’ (NSDQ:MDRX) largest investors filed a lawsuit against the health IT services provider after CEO Glen Tullman refused to step down following the mass resignation of 3 board members and its chief financial officer when Tullman fired board chairman Phil Pead.
HealthCor Mgmt., which owns about 5% of Allscripts outstanding shares, sued in a Delaware court to block a company bylaw that would require that board nominations take place in January.
- Delcath prices $20M public offering at $1.50 per share
- Becton Dickinson enters 5-year $1B credit agreement
- Getinge raises $140M (SEK 1B) to refinance Atrium acquisition
- Stereotaxis closes 2 funding rounds worth a collective $18.5M
- Vibrynt gets halfway through a $5.5M funding round
- Biostem U.S. announces $5M private placement financing agreement
- Flowonix raises $25M for pain management drug pump
- SPR Therapeutics wins $900k Ohio state loan
- Cambridge Heart sells $2.5M in investment rights in 2 subscription agreements
- CareFusion (NYSE:CFN): CLSA upgrades from "outperform" rating to "buy" rating, maintains $30 price target
- HeartWare International (NSDQ:HTWR): Cannacord Genuity reinstates "buy" rating
- Hospira (NYSE:HSP): Leerink Swann maintains "market perform" rating, $36 price target
- Siemens (NYSE:SI): Deutsche Bank upgrades to "buy" rating
- Uroplasty (NSDQ:UPI): Craig-Hallum maintains "buy" rating and $4.50 price target; Dougherty & Co. raises price target from $5 to $5.50, maintains "buy" rating; JMP Securities raises to $6 price target and upgrades to "market outperform" rating